Nathan D Seligson, Pharm.D.
Clinical Assistant Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(904) 244-9590
Business Email:
nseligson@ufl.edu
About Nathan D Seligson
Dr. Seligson earned his Doctor of Pharmacy degree from the University of South Florida prior to completing a pharmacy practice residency. Dr. Seligson then completed a post-doctoral fellowship in translational hematology/oncology focused on precision medicine in sarcoma.
Dr. Seligson is a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research. His clinical practice includes activities as a clinical pharmacogenomics specialist and hematology/oncology research scientist at Nemours Children’s Specialty Care in Jacksonville, Florida.
Dr. Seligson has been published in as first author in leading journals including: JAMA Open Network, The Oncologist, and npj Precision Medicine. His current research includes work to better understand cancer biology and tumor evolution in order to provide actionable molecular subtyping and pharmacogenomic therapy guidance in sarcoma.
Teaching Profile
Courses Taught
2020,2022-2025
PHA6136 Clinical Applications of Precision Medicine: Oncology
2021,2023-2024
PHA6935 Selected Topics in Pharmacy
2021-2024
PHA5012 App Personalized Med
Publications
Academic Articles
2024
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
Journal for immunotherapy of cancer.
12(9)
[DOI] 10.1136/jitc-2024-009472.
[PMID] 39343511.
2024
Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
The Annals of pharmacotherapy.
58(4):407-415
[DOI] 10.1177/10600280231187421.
[PMID] 37466080.
2024
Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566
Cancers.
16(21)
[DOI] 10.3390/cancers16213595.
[PMID] 39518158.
2024
Molecular markers of proliferation, DNA repair, and immune infiltration defines high-risk subset of resectable retroperitoneal sarcomas.
Surgical oncology.
56
[DOI] 10.1016/j.suronc.2024.102125.
[PMID] 39213836.
2023
CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas.
Molecular carcinogenesis.
62(8):1201-1212
[DOI] 10.1002/mc.23556.
[PMID] 37132760.
2023
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institution.
Clinical and translational science.
16(8):1352-1358
[DOI] 10.1111/cts.13539.
[PMID] 37415296.
2023
CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation.
Frontiers in pharmacology.
14
[DOI] 10.3389/fphar.2023.1334440.
[PMID] 38259277.
2023
Gene partners of the EWSR1 fusion may represent molecularly distinct entities.
Translational oncology.
38
[DOI] 10.1016/j.tranon.2023.101795.
[PMID] 37797367.
2023
Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.
Blood advances.
7(9):1769-1783
[DOI] 10.1182/bloodadvances.2022007934.
[PMID] 36111891.
2023
Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer.
Pharmacogenomics.
24(13):731-738
[DOI] 10.2217/pgs-2023-0125.
[PMID] 37702060.
2023
PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant.
Haematologica.
108(8):2155-2166
[DOI] 10.3324/haematol.2022.282399.
[PMID] 36861411.
2022
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
JCO precision oncology.
6
[DOI] 10.1200/PO.21.00211.
[PMID] 35108033.
2022
Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.
Thyroid : official journal of the American Thyroid Association.
32(10):1184-1192
[DOI] 10.1089/thy.2022.0115.
[PMID] 35658604.
2022
Development of a Campus-Wide Community Service Initiative during a Pandemic.
Pharmacy (Basel, Switzerland).
10(3)
[DOI] 10.3390/pharmacy10030047.
[PMID] 35645326.
2022
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.
NPJ precision oncology.
6(1)
[DOI] 10.1038/s41698-022-00271-x.
[PMID] 35468996.
2021
Adding the second T: Elevating STAR to START for behavioral interviewing.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
78(1):18-21
[DOI] 10.1093/ajhp/zxaa356.
[PMID] 33155021.
2021
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Clinical pharmacology and therapeutics.
109(2):334-342
[DOI] 10.1002/cpt.1946.
[PMID] 32535906.
2021
Evaluation of the timing of MRSA PCR nasal screening: How long can a negative assay be used to rule out MRSA-positive respiratory cultures?
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
78(Supplement_2):S57-S61
[DOI] 10.1093/ajhp/zxab109.
[PMID] 33788910.
2021
Key Considerations for Selecting a Genomic Decision Support Platform for Implementing Pharmacogenomics.
Clinical pharmacology and therapeutics.
110(3):555-558
[DOI] 10.1002/cpt.2328.
[PMID] 34254671.
2021
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.
NPJ precision oncology.
5(1)
[DOI] 10.1038/s41698-021-00177-0.
[PMID] 34021224.
2021
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
The Annals of pharmacotherapy.
55(7):921-931
[DOI] 10.1177/1060028020966548.
[PMID] 33070624.
2021
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.
Cancers.
13(7)
[DOI] 10.3390/cancers13071566.
[PMID] 33805415.
2020
Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation.
Anticancer research.
40(10):5707-5713
[DOI] 10.21873/anticanres.14585.
[PMID] 32988896.
2020
Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives.
Cell death discovery.
6
[DOI] 10.1038/s41420-020-0286-z.
[PMID] 32566256.
2020
Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis.
Cancer metastasis reviews.
39(2):553-566
[DOI] 10.1007/s10555-020-09866-x.
[PMID] 32020420.
2020
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity.
Journal of the American Medical Informatics Association : JAMIA.
27(11):1808-1812
[DOI] 10.1093/jamia/ocaa159.
[PMID] 32885823.
2019
BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
The oncologist.
24(7):973-979
[DOI] 10.1634/theoncologist.2018-0448.
[PMID] 30541756.
2019
Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma.
JAMA network open.
2(10)
[DOI] 10.1001/jamanetworkopen.2019.12416.
[PMID] 31577358.
2019
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.
The oncologist.
24(7):989-996
[DOI] 10.1634/theoncologist.2019-0047.
[PMID] 31019022.
2019
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Oncotarget.
10(55):5671-5679
[DOI] 10.18632/oncotarget.27144.
[PMID] 31620242.
2019
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Molecular carcinogenesis.
58(12):2327-2339
[DOI] 10.1002/mc.23121.
[PMID] 31544312.
2018
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
The Annals of pharmacotherapy.
52(5):439-445
[DOI] 10.1177/1060028017749214.
[PMID] 29241342.
Grants
May 2022
ACTIVE
Patterns of resistance to initial therapeutic treatment in Ewings Sarcoma
Role: Principal Investigator
Funding: Hematology/Oncology Pharmacy Asso Fou
Jan 2022
ACTIVE
American Cancer Society Institutional Research Grant
Role: Project Manager
Funding: AMERICAN CANCER SOCIETY
Education
Post-doctoral Fellowship in Translational Hematology/Oncology
2016-2019
·
The Ohio State University
PGY1 Pharmacy Practice Residency
2015-2016
·
Baptist Memorial Healthcare – Memphis
Pharm.D.
2011-2015
·
University of South Florida
B.S.
2007-2011
·
University of Central Florida
Contact Details
Phones:
- Business:
- (904) 244-9590
Emails:
- Business:
- nseligson@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
580 W 8TH ST
JACKSONVILLE FL 32209